NCT05610072View on ClinicalTrials.gov

Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Cocaine Use DisorderOpioid Use Disorder
Interventions
DRUG

n-acetylcysteine

Subjects will be randomized to receive 2.4 oral n-acetylcysteine daily.

DRUG

Hydromorphone

Subjects will receive up to 192 mg oral hydromorphone daily.

DRUG

Placebo n-acetylcystine

Subjects will be randomized to receive placebo n-acetylcysteine daily.

DRUG

Placebo hydromorphone

Prior to some experimental sessions, subjects will receive placebo hydromorphone

Trial Locations (2)

40507

RECRUITING

University of Kentucky Laboratory of Human Behavioral Pharmacology, Lexington

40536-0086

RECRUITING

University of Kentucky Department of Behavioral Science, Lexington

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

William Stoops

OTHER